These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33955860)

  • 1. Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?
    Ay Y; Toret E; Gozmen S; Cubukcu D; Karapinar TH; Oymak Y; Vergin RC
    Blood Coagul Fibrinolysis; 2021 Jun; 32(4):259-265. PubMed ID: 33955860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors?
    Salinas V; Carmona R; Mohammed BM; Martin EJ; Brophy DF; Young G
    Haemophilia; 2015 May; 21(3):398-404. PubMed ID: 25495850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
    Al Hawaj MA; Martin EJ; Venitz J; Barrett JC; Kuhn JG; Nolte ME; Brophy DF
    Haemophilia; 2013 May; 19(3):409-14. PubMed ID: 23510278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoğlu B; Kavakli K
    Haemophilia; 2012 Nov; 18(6):911-6. PubMed ID: 22639879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
    Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
    Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.
    Måseide RJ; Berntorp E; Nummi V; Lassila R; Tjønnfjord GE; Holme PA
    Haemophilia; 2021 Sep; 27(5):793-801. PubMed ID: 34106506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.
    Vila V; Aznar JA; Moret A; Marco A; Navarro S; Vila C; España F
    Haemophilia; 2013 Mar; 19(2):318-21. PubMed ID: 23174035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
    Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    Dargaud Y; Béguin S; Lienhart A; Al Dieri R; Trzeciak C; Bordet JC; Hemker HC; Negrier C
    Thromb Haemost; 2005 Mar; 93(3):475-80. PubMed ID: 15735797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
    Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
    Bassus S; Wegert W; Krause M; Escuriola-Ettinghausen C; Siegemund A; Petros S; Scholz T; Scharrer I; Kreuz W; Engelmann L; Kirchmaier CM
    Platelets; 2006 Sep; 17(6):378-84. PubMed ID: 16973498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia.
    Kumar R; Bouskill V; Schneiderman JE; Pluthero FG; Kahr WH; Craik A; Clark D; Whitney K; Zhang C; Rand ML; Carcao M
    Thromb Haemost; 2016 Jun; 115(6):1120-8. PubMed ID: 26917411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
    Samuelson Bannow B; Recht M; Négrier C; Hermans C; Berntorp E; Eichler H; Mancuso ME; Klamroth R; O'Hara J; Santagostino E; Matsushita T; Kessler C
    Blood Rev; 2019 May; 35():43-50. PubMed ID: 30922616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.